Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598853 (
forgetting
)
3,232
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study sought to identify specific opioid receptor subtypes involved in the modulation of reactivation of amnesic or forgotten memory traces by use of a one-trial inhibitory avoidance training procedures in mice. The effects of naloxone, ICI 174,864 (mu and
delta opioid receptor
antagonists, respectively) and dynorphin (kappa agonist) were investigated. The results indicated that preretention test administration of naloxone (2 mg/kg) or ICI 174,864 (3 mg/kg) attenuated the amnesia and
forgetting
as indicated by prolongation of step-through latency. On the other hand, the activation of kappa opioid receptors by dynorphin (1 mg/kg) also showed reactivating effects both after amnesia and
forgetting
. On the basis of the parallelism of the effects for mu and
delta opioid receptor
antagonists and kappa agonist, and on the finding that all three opioids demonstrated a different degree of reactivation of amnesic and forgotten memory traces, it was concluded that mu, delta, and kappa opioid receptors contribute to the modulation of amnesia and
forgetting
by independent mechanisms.
...
PMID:Memory retrieval enhancement by kappa opioid agonist and mu, delta antagonists. 858 5